Atrion (NASDAQ:ATRI) Sees Unusually-High Trading Volume

Atrion Co. (NASDAQ:ATRI) shares saw an uptick in trading volume on Thursday . 12,633 shares changed hands during trading, a decline of 20% from the previous session’s volume of 15,836 shares.The stock last traded at $426.56 and had previously closed at $427.58.

Analyst Ratings Changes

Separately, StockNews.com raised Atrion from a “sell” rating to a “hold” rating in a research note on Friday, March 1st.

Atrion Stock Down 0.9 %

The company has a market cap of $702.86 million, a price-to-earnings ratio of 36.21 and a beta of 0.60. The business has a fifty day simple moving average of $397.15 and a 200 day simple moving average of $365.69.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share (EPS) for the quarter. The company had revenue of $43.58 million during the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were given a $2.20 dividend. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a dividend yield of 2.20%. Atrion’s dividend payout ratio is presently 79.78%.

Hedge Funds Weigh In On Atrion

A number of institutional investors have recently made changes to their positions in ATRI. Copeland Capital Management LLC boosted its position in Atrion by 56.4% during the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 31 shares during the last quarter. Quadrant Capital Group LLC purchased a new stake in shares of Atrion in the fourth quarter valued at $36,000. FMR LLC lifted its position in Atrion by 38.0% during the first quarter. FMR LLC now owns 69 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 19 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Atrion in the 3rd quarter worth about $60,000. Finally, Advisor Group Holdings Inc. purchased a new stake in Atrion in the 4th quarter valued at about $65,000. 66.19% of the stock is owned by institutional investors and hedge funds.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.